A Case of Lenvatinib-Induced Focal Segmental Glomerulosclerosis (FSGS) in Metastatic Medullary Thyroid Cancer

We describe a case of lenvatinib (E7080) associated focal segmental glomerulosclerosis (FSGS) encountered during the treatment of metastatic medullary thyroid cancer. Proteinuria is a relatively common side effect of VEGF-targeted treatments and can occasionally result in treatment discontinuation....

Full description

Bibliographic Details

Published in:	Case Reports in Oncological Medicine
Main Authors:	Kathryn Fleming, James McGuinness, David Kipgen, Hilary Glen, Pavlina Spiliopoulou
Format:	Article
Language:	English
Published:	Wiley 2018-01-01
Online Access:	http://dx.doi.org/10.1155/2018/6927639